# Guangzhou Guoju Venture Capital > Guangzhou Guoju Venture Capital is a VC fund backing Medical and Biotechnology. See 10 investments, check sizes, portfolio. Updated Aug 2026. - Type: VC Fund - Total investments: 10 - Last investment: Feb 2026 - Lead investor: 20% - Last updated: Aug 2026 Guangzhou Guoju Venture Capital is an investment firm. ## Investment focus ### Industry | Industry | Investments | Share | | --- | --- | --- | | Medical | 7 | 70% | | Biotechnology | 6 | 60% | | Health Care | 5 | 50% | | Therapeutics | 3 | 30% | | Medical Device | 3 | 30% | 9 industries tracked in total. ### Stage | Stage | Investments | Share | | --- | --- | --- | | Series B | 5 | 50% | | Series A | 2 | 20% | | Series C | 2 | 20% | | Seed | 1 | 10% | ### Country | Country | Investments | Share | | --- | --- | --- | | China | 8 | 80% | | Japan | 1 | 10% | | Singapore | 1 | 10% | ## Investments | Company | Description | Amount | Stage | Date | Website | | --- | --- | --- | --- | --- | --- | | Sider Medical | Sider Medical is a smart healthcare R&D platform that focuses on microsystem medical device technology, integrating 5G, mobile internet, big data, cloud computing, and artificial intelligence medical image processing. | | Series B | Feb 11, 2026 | | | Langmu Medical | Langmu Medical is a technology-driven start-up dedicated to the research, development, and commercialization of innovative ophthalmic medical devices, aiming to improve clinical outcomes and advance eye care through cutting-edge technology. | $14.3M | Series A | Jan 05, 2026 | | | Nuwacell | Nuwacell focuses on the research and development, production and clinical transformation application of iPSC-derived cell therapy products. | $20.9M | Series B | Nov 08, 2024 | | | Femtosecond Technology | Femtosecond Technology is a developer of label-free biological imaging technology.Femtosecond Technology is a high-tech, "specialized and innovative" firm focusing on the application of femtosecond laser technology in clinical diagnosis and treatment, as well as biomedical industrialization. | $14.1M | Series A | Nov 04, 2024 | | | Lion TCR | They are a clinical-stage biotechnology company that develops TCR-T cell therapy for cancers and life-threatening infectious diseases in Asia. For the past decade, they have accumulated expertise covering the entire product development process, ranging from basic research, T cell engineering and development, and preclinical/clinicalassessment. Led by industry and academic experts from their base in Singapore, they are dedicated to the commercialization and continued development of their immunotherapy products. | $41.6M | Series B | Jun 27, 2023 | | | EnCureGen Pharmaceuticals | Huizhengqi Medicine is a pharmaceutical company that develops mRNA drugs for the treatment of tumor and immunity diseases. | | Seed | Jun 08, 2023 | | | Reforgene Medicine | Reforgene Medicine is a biomedical company that uses gene editing and genomic technology to develop new drugs intended to cure genetic diseases. | $15M | Series B | Apr 28, 2023 | | | PackGene Biotech | PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, wedeliver cost-effective, dependable, and scalable production solutions. | | Series C | Apr 18, 2023 | | | Raynovent | Raynovent is a science-driven innovative biotech company. | $53.6M | Series C | Dec 30, 2022 | | | Zhongguancun Shuimu Medical Technology | Shuimu Medical is a third-party professional medical device inspection and testing institution. | | Series B | | | 10 of 10 investments shown. ## Co-investors - [Guangzhou Industrial Investment Group](https://shizune.co/investors/profile/guangzhou-industrial-investment-group) — VC Fund, 4 deals together - [Guangzhou Development District Industrial Fund](https://shizune.co/investors/profile/guangzhou-development-district-industrial-fund-cc49) — VC Fund, 3 deals together - IFSC — VC Fund, 2 deals together - [Xinxing Fund](https://shizune.co/investors/profile/xinxing-fund) — VC Fund, 2 deals together - [Alwin Capital](https://shizune.co/investors/profile/alwin-capital) — VC Fund, 1 deal together - [BioTrack Capital](https://shizune.co/investors/profile/biotrack-capital) — VC Fund, 1 deal together ## Similar investors ### Similar stage - [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund - [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund - [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund ## FAQ ### What does Guangzhou Guoju Venture Capital invest in? Guangzhou Guoju Venture Capital invests primarily in Medical, Biotechnology and Health Care startups, most often at Series B and Series A stage. Most of the 10 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio. ### When did Guangzhou Guoju Venture Capital last invest? The most recent investment recorded for Guangzhou Guoju Venture Capital closed in Feb 2026. Shizune tracks 10 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly. ### Is Shizune's investor data accurate? Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page. # About Shizune Shizune.co is an investor database. Core features: - 48,091 startup investors (angels, VCs, accelerators, and others) - Email, phone, LinkedIn (for intros), socials, and other contact data - Updated daily from public funding news - CSV and Excel export The User can access the full database FOR FREE after signing up: shizune.co